OmniAb (OABI) Research Hub

OmniAb (OABI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.61 USD (-1.07%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.59, market cap 0.25B. This hub links to the full technical, earnings and options research available for OABI.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close4.61 USD (-1.07%)
52-week range1.9 USD – 5.132 USD
Trend regimeRange
14-day RSI57.6 (Bullish)
Trailing P/E-4.59
Market cap0.25B
Dividend yield0.00%
Next earnings2026-08-06

Available research for OABI

Earnings

OABI earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -4.59. Updated 2026-07-23.

Options: Covered Call

Covered Call on OABI: how it works, illustrative setup around the real 4.61 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on OABI: how it works, illustrative setup around the real 4.61 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on OABI: how it works, illustrative setup around the real 4.61 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

OABI technical analysis: range, last 4.61 USD, RSI 57.6, 52w range 1.9 USD–5.132 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is OABI in?

OmniAb (OABI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is OABI in an uptrend or downtrend?

As of 2026-10-26, OABI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is OABI's trailing P/E ratio?

OABI's trailing P/E is -4.59, with a market cap of 0.25B. See the earnings research page for full valuation detail.

When does OABI next report earnings?

OABI is next scheduled to report earnings on 2026-08-06.